Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | +0.86% | +15.20% | +24.34% |
Mar. 26 | North American Morning Briefing : Markets Steady -2- | DJ |
Mar. 19 | Adicet Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3.57M | Capitalization | 193M |
---|---|---|---|---|---|
Net income 2024 * | -122M | Net income 2025 * | -125M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 54.1 x |
P/E ratio 2024 * |
-1.28
x | P/E ratio 2025 * |
-1.25
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Adicet Bio, Inc.
1 day | +0.86% | ||
1 week | +15.20% | ||
1 month | +0.86% | ||
3 months | +35.06% | ||
6 months | +65.49% | ||
Current year | +24.34% |
Managers | Title | Age | Since |
---|---|---|---|
Aya Jakobovits
FOU | Founder | 71 | 14-10-31 |
Chen Schor
CEO | Chief Executive Officer | 51 | 16-06-30 |
Brian Harvey
DFI | Director of Finance/CFO | 63 | 20-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steve Dubin
BRD | Director/Board Member | 70 | 20-09-14 |
Carl Gordon
CHM | Chairman | 59 | 15-08-14 |
Michael Kauffman
BRD | Director/Board Member | 64 | 21-11-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 8 M€ | +9.75% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.35 | +0.86% | 534,078 |
24-03-27 | 2.33 | +4.02% | 614,658 |
24-03-26 | 2.24 | +1.82% | 804,997 |
24-03-25 | 2.2 | +0.46% | 645,392 |
24-03-22 | 2.19 | +7.35% | 944,774 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.34% | 193M | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |